Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 264

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 264
---
, to determine a preliminary 122 valuation for OmnigenicsAI. At that time, Union Acquisition Group’s team started to review the comparable valuations in the private and public markets, including many notable precision medicine companies’ valuations and market potential, and reviewed an analysis on the current market competitors. During the week of March 20, 2023, Mr. Calmet held in -personmeetings with potential investors in Mexico, who were introduced by Mr. Bransfield, to discuss about the business combination opportunity and the development of the business in the Mexican market. The objective was, in addition to finding partners to build a wet -labin Mexico, to find strategic partners to scale OmnigenicsAI’s product portfolio. These investors and partners ranged from investment funds to laboratories. On April 20, 2023, Mr. Calmet had a call with Mr. Ramondt, Co -Founderand Chief Financial Officer of MultiplAI, whom he had previously met previously in October 2022, to discuss the businesses of OmnigenicsAI and MultiplAI. During that call, Messrs. Calmet and Ramondt discussed potential synergies between both companies and a potential business combination between OmnigenicsAI and MultiplAI. The idea of drafting a letter of intent (“LOI”) to pursue the deal was discussed. Subsequently, on April 24, 2023, Mr. Calmet shared with Mr. Bransfield notes of the MultiplAI meeting, which were later discussed in a call that same day. During that call, the possibility of adding an additional deal with MultiplAI for a business combination transaction was explored. MultiplAI is unrelated to, and shares no common ownership with, the Parent, the Sponsor, the Initial Sponsor, Theo, Union Acquisition Group, Heritas or Bioceres. After the call, representatives of MultiplAI and OmnigenicsAI began sharing information on products, financials, organizational and legal documents to conduct a high -levelbusiness due diligence, in parallel to the drafting of an LOI. On May 9, 2023, Mr. Calmet introduced Mr. Ramondt to Mr. Bransfield during a three -waycall. During this call, the parties discussed the possibility of a business combination transaction that would include OmnigenicsAI merging with a SPAC and acquiring MultiplAI with the use of proceeds of the de -SPACtransaction. The parties also discussed potential ideas as to what the Combined Company would